62
RANDOMIZED CONTROLLED TRIAL ON ORAL ADMINISTRATION OF LACTOBACILLUS CASEI DG FOR 8 WEEKS AFTER ILEOSTOMY CLOSURE (MICROBIOTA AND IMMUNE (MICROENVIRONMENT IN POUCHITIS.-MEP1- NCT03136419).
Date
May 18, 2024
Tracks
Related Products
EFFECT OF SCREENING STRATEGIES ON THE NATURAL HISTORY OF IBD-RELATED AND SPORADIC COLORECTAL CANCER
BACKGROUND: Inflammatory bowel disease encompasses two types of idiopathic intestinal disease, ulcerative colitis (UC) and Crohn's disease (CD) that are differentiated by their location and depth of involvement in the bowel wall…
IMMUNOREACT 10: INFLUENCE OF BMI IN THE IMMUNOLOGICAL MICROENVIRONMENT OF PERITUMORAL HEALTHY MUCOSA IN RECTAL ADENOCARCINOMA
INTRODUCTION: Due to its rarity, anal adenocarcinoma (AA) does not have a standardized staging system. The tumor (T) stage of an adenocarcinoma arising from the anal canal could be based on depth of invasion, as for rectal adenocarcinoma, or on size, as in anal squamous cell carcinoma…
IMMUNOREACT 8: IMMUNE MARKERS AS PREDICTORS OF LOCAL TUMOR SPREAD IN PATIENTS UNDERGOING TRANSANAL EXCISION FOR RECTAL CANCER
BACKGROUND: Local excision (LE) with transanal endoscopic microsurgery (TEM) is an established alternative to radical resection in select early rectal cancers and high-risk patients…
IMMUNOREACT 3: PERITUMORAL IMMUNE MICROENVIRONMENT MARKERS AS PREDICTORS OF RECURRENCE AFTER ADJUVANT THERAPY IN LOCALLY ADVANCED RECTAL CANCER
BACKGROUND: Adjuvant therapy after rectal cancer surgery is indicated in T4N0 or any T and nodal metastasis and/or risk factors for recurrences…